PROMISe trial: A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids

Vanessa L. Jacoby, Maureen P. Kohi, Liina Poder, Alison Jacoby, Jeanette Lager, Michael Schembri, Viola Rieke, Deborah Grady, Eric Vittinghoff, Fergus Coakley

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective To evaluate the feasibility of a full-scale placebo-controlled trial of magnetic resonance-guided focused ultrasound for fibroids (MRgFUS) and obtain estimates of safety and efficacy. Design Pilot, randomized, placebo-controlled trial. Setting University medical center. Patient(s) Premenopausal women with symptomatic uterine fibroids. Intervention(s) Participants randomized in a 2:1 ratio to receive MRgFUS or placebo procedure. Main Outcome Measure(s) Primary outcome: change in fibroid symptoms from baseline to 4 and 12 weeks after treatment assessed by the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QOL); secondary outcome: incidence of surgery or procedures for recurrent symptoms at 12 and 24 months. Result(s) Twenty women with a mean age of 44 years (±standard deviation 5.4 years) were enrolled, and 13 were randomly assigned to MRgFUS and 7 to placebo. Four weeks after treatment, all participants reported improvement in the UFS-QOL: a mean of 10 points in the MRgFUS group and 9 points in the placebo group (for difference in change between groups). By 12 weeks, the MRgFUS group had improved more than the placebo group (mean 31 points and 13 points, respectively). The mean fibroid volume decreased 18% in the MRgFUS group with no decrease in the placebo group at 12 weeks. Two years after MRgFUS, 4 of 12 women who had a follow-up evaluation (30%) had undergone another fibroid surgery or procedure. Conclusion(s) Women with fibroids were willing to enroll in a randomized, placebo-controlled trial of MRgFUS. A placebo effect may explain some of the improvement in fibroid-related symptoms observed in the first 12 weeks after MRgFUS.

Original languageEnglish (US)
Pages (from-to)773-780
Number of pages8
JournalFertility and Sterility
Volume105
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Leiomyoma
Magnetic Resonance Spectroscopy
Randomized Controlled Trials
Placebos
Quality of Life
Placebo Effect

Keywords

  • MR-guided focused ultrasound
  • uterine fibroids

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

PROMISe trial : A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. / Jacoby, Vanessa L.; Kohi, Maureen P.; Poder, Liina; Jacoby, Alison; Lager, Jeanette; Schembri, Michael; Rieke, Viola; Grady, Deborah; Vittinghoff, Eric; Coakley, Fergus.

In: Fertility and Sterility, Vol. 105, No. 3, 01.03.2016, p. 773-780.

Research output: Contribution to journalArticle

Jacoby, VL, Kohi, MP, Poder, L, Jacoby, A, Lager, J, Schembri, M, Rieke, V, Grady, D, Vittinghoff, E & Coakley, F 2016, 'PROMISe trial: A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids', Fertility and Sterility, vol. 105, no. 3, pp. 773-780. https://doi.org/10.1016/j.fertnstert.2015.11.014
Jacoby, Vanessa L. ; Kohi, Maureen P. ; Poder, Liina ; Jacoby, Alison ; Lager, Jeanette ; Schembri, Michael ; Rieke, Viola ; Grady, Deborah ; Vittinghoff, Eric ; Coakley, Fergus. / PROMISe trial : A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. In: Fertility and Sterility. 2016 ; Vol. 105, No. 3. pp. 773-780.
@article{e11841711fe34d49b618def7e2298c79,
title = "PROMISe trial: A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids",
abstract = "Objective To evaluate the feasibility of a full-scale placebo-controlled trial of magnetic resonance-guided focused ultrasound for fibroids (MRgFUS) and obtain estimates of safety and efficacy. Design Pilot, randomized, placebo-controlled trial. Setting University medical center. Patient(s) Premenopausal women with symptomatic uterine fibroids. Intervention(s) Participants randomized in a 2:1 ratio to receive MRgFUS or placebo procedure. Main Outcome Measure(s) Primary outcome: change in fibroid symptoms from baseline to 4 and 12 weeks after treatment assessed by the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QOL); secondary outcome: incidence of surgery or procedures for recurrent symptoms at 12 and 24 months. Result(s) Twenty women with a mean age of 44 years (±standard deviation 5.4 years) were enrolled, and 13 were randomly assigned to MRgFUS and 7 to placebo. Four weeks after treatment, all participants reported improvement in the UFS-QOL: a mean of 10 points in the MRgFUS group and 9 points in the placebo group (for difference in change between groups). By 12 weeks, the MRgFUS group had improved more than the placebo group (mean 31 points and 13 points, respectively). The mean fibroid volume decreased 18{\%} in the MRgFUS group with no decrease in the placebo group at 12 weeks. Two years after MRgFUS, 4 of 12 women who had a follow-up evaluation (30{\%}) had undergone another fibroid surgery or procedure. Conclusion(s) Women with fibroids were willing to enroll in a randomized, placebo-controlled trial of MRgFUS. A placebo effect may explain some of the improvement in fibroid-related symptoms observed in the first 12 weeks after MRgFUS.",
keywords = "MR-guided focused ultrasound, uterine fibroids",
author = "Jacoby, {Vanessa L.} and Kohi, {Maureen P.} and Liina Poder and Alison Jacoby and Jeanette Lager and Michael Schembri and Viola Rieke and Deborah Grady and Eric Vittinghoff and Fergus Coakley",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.fertnstert.2015.11.014",
language = "English (US)",
volume = "105",
pages = "773--780",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - PROMISe trial

T2 - A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids

AU - Jacoby, Vanessa L.

AU - Kohi, Maureen P.

AU - Poder, Liina

AU - Jacoby, Alison

AU - Lager, Jeanette

AU - Schembri, Michael

AU - Rieke, Viola

AU - Grady, Deborah

AU - Vittinghoff, Eric

AU - Coakley, Fergus

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective To evaluate the feasibility of a full-scale placebo-controlled trial of magnetic resonance-guided focused ultrasound for fibroids (MRgFUS) and obtain estimates of safety and efficacy. Design Pilot, randomized, placebo-controlled trial. Setting University medical center. Patient(s) Premenopausal women with symptomatic uterine fibroids. Intervention(s) Participants randomized in a 2:1 ratio to receive MRgFUS or placebo procedure. Main Outcome Measure(s) Primary outcome: change in fibroid symptoms from baseline to 4 and 12 weeks after treatment assessed by the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QOL); secondary outcome: incidence of surgery or procedures for recurrent symptoms at 12 and 24 months. Result(s) Twenty women with a mean age of 44 years (±standard deviation 5.4 years) were enrolled, and 13 were randomly assigned to MRgFUS and 7 to placebo. Four weeks after treatment, all participants reported improvement in the UFS-QOL: a mean of 10 points in the MRgFUS group and 9 points in the placebo group (for difference in change between groups). By 12 weeks, the MRgFUS group had improved more than the placebo group (mean 31 points and 13 points, respectively). The mean fibroid volume decreased 18% in the MRgFUS group with no decrease in the placebo group at 12 weeks. Two years after MRgFUS, 4 of 12 women who had a follow-up evaluation (30%) had undergone another fibroid surgery or procedure. Conclusion(s) Women with fibroids were willing to enroll in a randomized, placebo-controlled trial of MRgFUS. A placebo effect may explain some of the improvement in fibroid-related symptoms observed in the first 12 weeks after MRgFUS.

AB - Objective To evaluate the feasibility of a full-scale placebo-controlled trial of magnetic resonance-guided focused ultrasound for fibroids (MRgFUS) and obtain estimates of safety and efficacy. Design Pilot, randomized, placebo-controlled trial. Setting University medical center. Patient(s) Premenopausal women with symptomatic uterine fibroids. Intervention(s) Participants randomized in a 2:1 ratio to receive MRgFUS or placebo procedure. Main Outcome Measure(s) Primary outcome: change in fibroid symptoms from baseline to 4 and 12 weeks after treatment assessed by the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QOL); secondary outcome: incidence of surgery or procedures for recurrent symptoms at 12 and 24 months. Result(s) Twenty women with a mean age of 44 years (±standard deviation 5.4 years) were enrolled, and 13 were randomly assigned to MRgFUS and 7 to placebo. Four weeks after treatment, all participants reported improvement in the UFS-QOL: a mean of 10 points in the MRgFUS group and 9 points in the placebo group (for difference in change between groups). By 12 weeks, the MRgFUS group had improved more than the placebo group (mean 31 points and 13 points, respectively). The mean fibroid volume decreased 18% in the MRgFUS group with no decrease in the placebo group at 12 weeks. Two years after MRgFUS, 4 of 12 women who had a follow-up evaluation (30%) had undergone another fibroid surgery or procedure. Conclusion(s) Women with fibroids were willing to enroll in a randomized, placebo-controlled trial of MRgFUS. A placebo effect may explain some of the improvement in fibroid-related symptoms observed in the first 12 weeks after MRgFUS.

KW - MR-guided focused ultrasound

KW - uterine fibroids

UR - http://www.scopus.com/inward/record.url?scp=84959260296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959260296&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2015.11.014

DO - 10.1016/j.fertnstert.2015.11.014

M3 - Article

C2 - 26658133

AN - SCOPUS:84959260296

VL - 105

SP - 773

EP - 780

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 3

ER -